logo
logo

PK MED receives a non-dilutive DeepTech grant of 1.5 million Euros from Bpifrance for the development of a local cell homing implant to enhance bone marrow transplantation.

Jul 24, 2024•12 months ago

Amount Raised

€1.5 Million

ParisBiotechnologyHealth Care

Investors

Bpifrance

Description

PK MED, a privately owned French biotechnology company founded in 2019 by Truffle Capital, announced the receipt of a non-dilutive DeepTech grant of 1.5 million Euros from Bpifrance. The funding will accelerate the company's project PKM-02, which involves an innovative cell homing technology aimed at improving bone marrow transplantation for diseases with high medical needs such as leukemias and hemoglobinopathies.

Company Information

Company

PK MED

Location

Paris, Texas, United States

About

PK MED is a French biotechnology company founded in 2019 by Truffle Capital, specializing in developing injectable smart implants for drug release in rheumatology and cell homing in bone marrow transplantations. Their unique expertise and technological know-how enable the advancement of existing systemic treatments into new, safer, and more effective patented local therapies.

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Related People